Humulin M3 (Mixture 3) (Insulin Human (Rdna))

Humulin M3 is used as part of a comprehensive diabetes management plan to control blood glucose levels.

• For adults with type 1 diabetes requiring basal‑bolus insulin.
• For adults with type 2 diabetes when diet, exercise, and oral agents are insufficient.
• To provide mealtime (prandial) coverage together with basal insulin effect.
• Suitable for patients who prefer a fixed ratio of rapid and intermediate insulin in a single injection.
• May be used in hospital settings for insulin therapy adjustments.

• Humulin M3 delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production and lowering circulating glucose concentrations and improves metabolic homeostasis.

Like other insulin preparations, Humulin M3 can cause adverse reactions, which are generally categorized by frequency and severity.

Common

• Hypoglycemia, ranging from mild to severe.
• Redness, swelling, or pain at the injection site.
• Lipodystrophy (fat tissue changes) with repeated injections.
• Weight gain due to increased glucose utilization.
• Mild allergic rash or urticaria.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Anaphylactic reaction with difficulty breathing or swelling of the face.
• Significant hypokalemia causing muscle weakness or cardiac arrhythmia.

Healthcare providers should consider several precautions when prescribing Humulin M3 to ensure safe and effective use.

• Assess renal and hepatic function before initiating therapy.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose frequently to avoid hypoglycemia, especially in the elderly or pregnant patients.
• Educate patients on proper injection technique and rotation of sites to reduce lipodystrophy.
• Review concomitant medications that may mask hypoglycemia symptoms.
• Use caution in patients with a history of cardiovascular disease.

Humulin M3 may interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that can mask hypoglycemia symptoms.
• MAO‑inhibitors that may potentiate insulin’s glucose‑lowering effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Thiazide diuretics that can alter potassium levels and affect insulin sensitivity.